OTH

OTH Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of hematological malignancies and solid tumors. The company's primary research efforts center on targeting key transcriptional regulators, specifically Cyclin-dependent kinase 9 (CDK9) and Bromodomain-containing protein 4 (BRD4), which are frequently dysregulated in various cancers. By inhibiting these targets, OTH Therapeutics aims to disrupt the survival mechanisms of cancer cells and overcome resistance to existing therapies. The company is currently advancing its lead programs through lead optimization and IND-enabling studies, with a focus on achieving high potency and selectivity. OTH Therapeutics operates as a private entity, leveraging expertise in medicinal chemistry and oncology biology to build a robust pipeline of targeted therapies.